Phio Pharmaceuticals
PHIO
14 hedge funds and large institutions have $626K invested in Phio Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0.02% less ownership
Funds ownership: 0.07% → 0.05% (-0.02%)
13% less funds holding
Funds holding: 16 → 14 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
37% less capital invested
Capital invested by funds: $991K → $626K (-$365K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$44.1K |
| 2 |
Renaissance Technologies
New York
|
+$27.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.9K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$3.9K |
| 5 |
JP Morgan Chase
New York
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$146K |
| 2 |
Two Sigma Investments
New York
|
-$129K |
| 3 |
Millennium Management
New York
|
-$30.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $269K | +$16.9K | +178 | +7% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $95K | – | – | – |
|
|
3
Cetera Investment Advisers
Schaumburg,
Illinois
| $80K | +$44.1K | +463 | +125% |
|
|
4
Two Sigma Advisers
New York
| $41K | -$146K | -1,537 | -78% |
|
|
VF
5
Virtu Financial
New York
| $38K | -$6.19K | -65 | -14% |
|
|
6
Renaissance Technologies
New York
| $37K | +$27.6K | +290 | +309% |
|
7
BlackRock
New York
| $31K | -$1.43K | -15 | -4% |
|
|
TSS
8
Two Sigma Securities
New York
| $21K | +$3.9K | +41 | +24% |
|
|
9
Millennium Management
New York
| $9K | -$30.9K | -325 | -77% |
|
10
UBS Group
Zurich,
Switzerland
| $2K | -$3.81K | -40 | -62% |
|
11
Morgan Stanley
New York
| $1K | – | – | – |
|
12
Citigroup
New York
| $1K | +$857 | +9 | New |
|
|
13
JP Morgan Chase
New York
| $1K | +$1.05K | +11 | +367% |
|
|
14
Two Sigma Investments
New York
| – | -$129K | -1,192 | Closed |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$29K | -269 | Closed |
|
|
16
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$17K | -161 | Closed |
|
17
Group One Trading
Chicago,
Illinois
| – | -$286 | -3 | -50% |
|
PHIO Hedge Fund Activity: Q1 2022 in Review
14 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2022, worth a combined $626K — down 37% from $991K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PHIO and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Cetera Investment Advisers, adding an estimated $44.1K. The largest seller was Two Sigma Advisers, cutting an estimated $146K.
- 14 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2022, down from 16 in Q4 2021.
- Funds reported $626K of Phio Pharmaceuticals stock for Q1 2022, down 37% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q1 2022 and 3 closed out, a net change of -2 holders.
- The largest Phio Pharmaceuticals buyer in Q1 2022 was Cetera Investment Advisers, an estimated $44.1K added.
- The largest Phio Pharmaceuticals seller in Q1 2022 was Two Sigma Advisers, an estimated $146K sold.
Based on aggregated 13F filings for Q1 2022.